The following article features coverage from the ASCO Genitourinary Cancers Symposium 2022. Click here to read more of Cancer Therapy Advisor’s conference coverage.

Same-day discharge (SDD) following robot-assisted radical prostatectomy (RARP) is feasible and safe, with complication and readmission rates comparable to those of inpatient RARP, data reported at the ASCO Genitourinary Cancers Symposium 2022 indicate.

In addition, it is associated with high patient satisfaction rates and offers health care cost savings, according to investigators Michael Uy, MD, of McMaster University in Hamilton, Ontario, Canada, and colleagues.

“Data from this study will further inform the uptake and development of future SDD pathways in contemporary urological care such that it may be offered to a broader patient population,” Dr Uy’s team concluded in their study abstract.

Continue Reading

The findings are from a systematic review and meta-analysis of data from 14 studies (8 prospective and 6 retrospective cohort studies) with a pooled population of 3795 patients, including 2348 (61.9%) who underwent inpatient RARPs and 1447 (38.1%) who underwent SDD RARPs.

Compared with the inpatient RARP group, patients who had SDD RARPs did not differ significantly with respect to grade 3 or higher Clavien-Dindo complications, 90-day readmission rates, or unscheduled emergency department visits, according to the investigators. Cost savings per patient ranged from $367 to $2109 in US dollars. Overall satisfaction rates were high (87.5%-100%).

Read more of Cancer Therapy Advisor’s coverage of ASCO GU 2022 by visiting the conference page.


Uy M, Millan B, Jones C, et al. Successful same-day discharge for robot-assisted radical prostatectomy: A systematic review and meta-analysis. Presented at ASCO GU 2022; February 17-19, 2022. Abstract 238.

This article originally appeared on Renal and Urology News